Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Coherus Oncology's Tax Provisions history spans 3 years, with the latest figure at -$380000.0 for Q3 2023.

  • For Q3 2023, Tax Provisions changed N/A year-over-year to -$380000.0; the TTM value through Dec 2023 reached -$380000.0, changed N/A, while the annual FY2023 figure was -$380000.0, N/A changed from the prior year.
  • Tax Provisions for Q3 2023 was -$380000.0 at Coherus Oncology, down from $1.1 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.3 million in Q2 2020 and bottomed at -$380000.0 in Q3 2023.
  • The 3-year median for Tax Provisions is $847000.0 (2019), against an average of $576285.7.
  • The largest YoY upside for Tax Provisions was 2449.02% in 2020 against a maximum downside of 78.39% in 2020.
  • A 3-year view of Tax Provisions shows it stood at $847000.0 in 2019, then increased by 29.87% to $1.1 million in 2020, then plummeted by 134.55% to -$380000.0 in 2023.
  • Per Business Quant, the three most recent readings for CHRS's Tax Provisions are -$380000.0 (Q3 2023), $1.1 million (Q4 2020), and $183000.0 (Q3 2020).